BIAF Stock Analysis: Buy, Sell, or Hold?
BIAF - bioAffinity Technologies, Inc. Common Stock
$1.99
0.10 (5.29%)
▲
5d:
-6.13%
30d:
-32.08%
90d:
+80.91%
HOLD
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 21, 2026
5d
Get Alerted When BIAF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called BIAF this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BIAF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BIAF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BIAF is currently trading at $1.99, which is considered oversold relative to its 30-day fair value range of $2.03 to $3.30.
Technical Outlook: Technically, BIAF is in a uptrend. Immediate support is located at $1.81, while resistance sits at $2.42. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: BIAF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+201.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BIAF is in a uptrend. Immediate support is located at $1.81, while resistance sits at $2.42. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: BIAF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+201.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.03 -
$3.30
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.3%)
- BULLISH: Trading 201.5% below Wall St target ($6.00)
- CAUTION: Recommendation downgraded due to -6.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.03 -
$3.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.81
Resistance Level
$2.43
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.25
Wall Street Target
$6.00
(+201.5%)
Revenue Growth (YoY)
-27.8%
Profit Margin
-242.0%
Share & Embed Analysis
Last updated: May 14, 2026 7:27 PM ET
Data refreshes hourly during market hours. Next update: 8:27 PM
Data refreshes hourly during market hours. Next update: 8:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIAF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$620 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$250 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$130 | 59 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 58 HOLD |
